European patient survey on CAR T-cell therapy to gain insights into patients’ experiences, quality of life and unmet needs

*Last updated July 28, 2023.

Also available in:

Português

After months of preparation and close collaboration with patient advocacy groups, patients and carers, the T2EVOLVE and QUALITOP consortia are proud to launch their European patient survey on CAR T-cell therapy.

This survey will help to understand patients’ experiences with CAR T-cell therapy, evaluate the impact of this treatment on quality of life and identify unmet needs. With this information we aim to improve quality of life in patients receiving CAR T-cell therapy and their carers by optimizing support and improving the CAR T-cell treatment journey.

All European adult patients (≥ 18 years) who received CAR T-cell therapy for a hematologic malignancy (no specific indication required) can participate by filling in a digital survey.

Now, we need you!

If you are a patient treated with CAR T-cell therapy for a hematologic malignancy in Europe we would like to invite you to share your experiences with us by participating in our survey!

If you are not a patient but you are in close contact with patients who receive CAR T-cell therapy (e.g. a patient association, hematologist, nurse or other healthcare professional) we would like to invite you to help us by sharing this survey with patients! 🖨️

The survey is available in English, French, German, Spanish, Italian, Portuguese and Dutch.

2 WAYS TO ACCESS AND SHARE THE SURVEY 

(BEFORE October 31, 2023)

Password to enter the survey:
t2evolve